Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer mortality worldwide. The aim at Recolony is to bring a medication for CRC patients purely based on commensal bacteria: in vivo data show very high anti-tumor efficacy of this bacteria by specific activation of CD8+ T-cells. Recolony's therapy will minimize severe side-effects and reduce visits to the hospital, and it could even be applied to prevent tumor recurrence or avoid tumor development in risk patients.